Vanda Pharmaceuticals | VNDA - Interest Expense On Debt

Stock Price
7.44
Daily Change
0.02 0.27%
Monthly
0.40%
Yearly
56.63%
Q1 Forecast
4.24

Vanda Pharmaceuticals reported 601.14M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Akebia Therapeutics 364.15M 18.56M Sep/2025
Alnylam Pharmaceuticals USD 44.4M 4.15M Sep/2025
Anika Therapeutics 189.44M 1.76M Sep/2025
Arrowhead Research USD 22.5M 811K Dec/2025
AstraZeneca USD 484M 181M Dec/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
Esperion Therapeutics USD 15.08M 1.36M Sep/2024
Halozyme Therapeutics USD 4.3M 98K Sep/2025
Heron Therapeutics USD 500K 900K Sep/2024
Insmed USD 20.38M 863K Sep/2025
J&J USD 18M 290M Sep/2025
Lexicon Pharmaceuticals USD 2.21M 2.74M Jun/2024
Ligand Pharmaceuticals USD 910K 243K Sep/2025
Merck USD 412M 85M Dec/2025
Minerva Neurosciences USD 2.31M 60K Jun/2024
Moderna USD 12.14B 12.13B Sep/2025
Novartis USD 281M 8M Sep/2025
Pfizer USD 711M 59M Dec/2025
PTC Therapeutics USD 2.64B 2.61B Sep/2025
Puma Biotechnology USD 3.37M 11K Jun/2024
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sanofi EUR -25M 252M Dec/2025
Takeda JPY 123.63B 40.49B Dec/2025
Teva Pharmaceutical Industries USD 220M 17M Dec/2025
Ultragenyx Pharmaceutical USD 14.15M 108K Sep/2025
Vanda Pharmaceuticals 601.14M 23.61M Sep/2025
Veracyte USD 2K 1000 Dec/2023